Drug Database
LA

lansoprazole + amoxicillin + clarithromycin (Lansap)

✓ Approved

Takeda · ATP4A · 小分子

什么是 lansoprazole + amoxicillin + clarithromycin?

lansoprazole + amoxicillin + clarithromycin 是一种小分子,由Takeda研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Lansap
公司Takeda
药物类别小分子
分子靶点ATP4A
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

lansoprazole + amoxicillin + clarithromycin 作用于 1 个分子靶点:

ATP4AATPase H+/K+ transporting subunit alpha (ATP6A)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

lansoprazole + amoxicillin + clarithromycin 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersGastric ulcer✓ Approved
Infections and infestationsHelicobacter infection✓ Approved

相关研究文献

PubMedBiosensors & bioelectronics2026-11-18

A microfluidic electrochemical immunosensor for dual detection of β-lactam antibiotics in milk and wastewater.

Kumari Surbhi S, Vergin Chantal C CC, Lange Thorid T, Devi Sarita S et al.

Rapid monitoring of β-lactam antibiotic residues in food and environmental-samples remains a significant challenge, as conventional analytical methods, although highly sensitive, are often labor-intensive, time-consuming, and dependent on sophisticated instrumentation. Herein, we present a novel microfluidic electrochemical immunosensing platform based on an easy-to-synthesize conductive Au@ACM-10 metal-organic framework nanocomposite coupled with 3-aminopropylphosphonic acid (APPA)-assisted functionalization of the MOF. The resulting platform establishes a robust dual-recognition system capable of ultrasensitive detection of both amoxicillin (AMX) and ampicillin (AMP) within a rapid 10-min response time. Under optimized conditions, the immunosensor achieved excellent analytical performance for AMX (LOD 1.211 ng/mL; LOQ 1.86 ng/mL; sensitivity 213.9 μA/log(ng/mL)-1) and AMP (LOD 1.213 ng/mL; LOQ 1.90 ng/mL; sensitivity 211.4 μA/log(ng/mL)-1). The practical utility of the platform was successfully validated with ELISA-screened milk and spiked treated effluent wastewater yielding reliable recoveries with minimal matrix interference. Furthermore, integrating modified SPGEs within a microfluidic flow-cell system significantly reduced sample and electrolyte consumption while enhancing device portability. Overall, this proposed microfluidic platform offers a highly promising approach for the rapid, on-site monitoring of β-lactam antibiotic residues in food safety and environmental surveillance applications.

PMID 43051014
阅读全文 →
PubMedMediterranean journal of hematology and infectious diseases2026-11-18

Antimicrobial Management Following Positive Pneumococcal Urinary Antigen Testing in Hospitalized Community-Acquired Pneumonia: A Retrospective Cohort Study.

Donga Maria M, Gorgulho Ana A, Bartilotti Francisca F, Mbanze Dara D et al.

Pneumococcal urinary antigen testing (PUAT) rapidly supports pneumococcal etiology in community-acquired pneumonia (CAP), but how positive results are incorporated into antimicrobial management in routine care remains uncertain. To characterize antimicrobial stewardship actions implemented after a positive PUAT result became available in hospitalized adults with CAP, identify potential areas for improving guideline-concordant antimicrobial management, and compare clinical outcomes according to individual stewardship measures. We conducted a retrospective observational cohort study at a Portuguese tertiary hospital including adults hospitalized with CAP and positive PUAT between January 2020 and December 2024. The primary endpoint was antimicrobial spectrum narrowing. Post-PUAT atypical coverage optimization and intravenous-to-oral switch were analyzed separately. Among 332 episodes, antimicrobial spectrum narrowing occurred in 30 (9.0%), after a median of 3 days (Q1-Q3, 2-4). De-escalation to ampicillin or amoxicillin occurred in 7 episodes (2.1%). Post-PUAT atypical coverage optimization occurred in 158 episodes (47.6%) and intravenous-to-oral switch in 71 (21.4%). Narrowing and intravenous-to-oral switch were associated with shorter length of stay in unadjusted analyses, although these associations were exploratory and potentially influenced by clinical stability. In hospitalized PUAT-positive CAP, antimicrobial spectrum narrowing was uncommon, whereas atypical coverage optimization was the most frequent prescribing change. Structured post-result reassessment pathways may help improve guideline-concordant antimicrobial management.

PMID 43048189
阅读全文 →
PubMedJournal of pediatric hematology/oncology2026-11-18

Epidemiology of Bloodstream Infections and Impact of Antibiotic Prophylaxis: A 10-Year Experience at a Tertiary Care Pediatric Oncology-Hematology Center in Italy.

De Leonardis Francesco F, Rando Roberta R, Ronga Luigi L, Koronica Roberta R et al.

Bloodstream infections (BSIs) are a leading cause of morbidity and mortality in pediatric oncology-hematology patients. The local epidemiological landscape varies across centers, requiring continuous institutional surveillance. BSI episodes at a tertiary pediatric oncology-hematology center (Bari, Italy) were retrospectively reviewed over 10 years (2014 to 2024), analyzing microbiological spectrum, antimicrobial susceptibility, and the impact of 2 prophylactic policies: amoxicillin-clavulanate prophylaxis (2014 to 2019) versus its discontinuation (2019 to 2024). Among 568 newly diagnosed patients, 208 BSIs were documented in 144 (25.4%), with 93.8% monomicrobial. Gram-positive organisms predominated (61.6%), with coagulase-negative staphylococci as the most frequent isolates. Escherichia coli was the leading Gram-negative pathogen (9.5%). Eight fungal BSIs occurred exclusively in hematologic malignancies, half caused by Candida parapsilosis; 2 were polymicrobial. Peak C-reactive protein independently predicted Gram-negative BSI in multivariable analysis (OR: 1.005; 95% CI: 1.001-1.010; P<0.05), with limited discriminatory performance (AUC: 0.62). Blood culture positivity was significantly higher during prophylaxis (5.75% vs. 3.65%; P<0.001). Multidrug-resistant organisms remained rare (3.8%), with no methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci detected. BSI-related mortality was 1.4%, confined to Gram-negative and fungal episodes. Prophylaxis discontinuation was associated with lower positivity rates. An empirical escalation strategy ensured adequate coverage while minimizing antibiotic exposure, supporting its use in this setting.

PMID 43050585
阅读全文 →
PubMedEnvironmental pollution (Barking, Essex : 1987)2026-11-18

Soil compartment selection shapes organic micropollutant exposure and risk in Mediterranean agroecosystems irrigated with reclaimed water.

Alonso L L LL, Castaño-Trias M M, Statiris E E, Salvoch M M et al.

Wastewater reuse for irrigation is increasingly necessary in Mediterranean regions affected by climate change effects as prolonged droughts, yet reclaimed water continuously introduces organic micropollutants (OMPs) that persist after treatment into agroecosystems. Here we investigated the occurrence, distribution and risks of 65 OMPs (55 pharmaceuticals, including metabolites, and 10 other wastewater-derived contaminants) in a Mediterranean lettuce field on Lesbos Island (Greece) irrigated with two reclaimed-water supplies over two growing seasons. Soils were sampled before planting, during growth and at harvest, distinguishing bulk soil (BS) from root-influenced soil (RS), while the rhizosphere (RZ) was analyzed to assess fate and bioavailability. OMPs were detected in all irrigation-water samples (6-38 compounds per sample), with broader profiles and higher loads in summer. Season explained OMP occurrence in soils more strongly than irrigation source. Levels of OMPs in root-influenced soil exceeded those in bulk soil in 69% of the cases, most markedly under the higher-load supply and in summer (median 2.5-fold). This identifies the root zone as the main accumulation hotspot, whereas the rhizosphere was decoupled from soil concentrations, indicating a non-redundant, potentially more bioavailable fraction. Soil concentrations predicted from irrigation-water data underestimated measured exposure levels for >80% of the detected compounds in both compartments, most strongly in the root zone. Fifteen compounds exceeded the risk threshold (RQ > 1), predominantly in summer, but risk was concentrated in a few OMPs: clindamycin, metoprolol acid, caffeine, clarithromycin and ofloxacin accounted for 91% of the cumulative risk, with antibiotics and pharmaceutical metabolites contributing 80%. By linking accumulation, exposure, and risk across soil compartments, this work helps identify the contaminants requiring more attention in agricultural soils irrigated with reclaimed water, an scenario set to become more frequent across Mediterranean region as climate change increases reliance on alternative water sources.

PMID 43051438
阅读全文 →
PubMedClinical oral investigations2026-11-18

Oral Staphylococcus carriage in healthy adults: prevalence, antimicrobial resistance, temporal patterns, and oral-nasal comparisons.

Fonseca Maeva M, Sousa Marta M, Campos Carla C, Campos Joana J et al.

The oral cavity is increasingly recognized as a reservoir of Staphylococcus species, yet knowledge gaps remain regarding species diversity, antimicrobial resistance (AMR), overlap with nasal carriage, and colonization persistence. Therefore, this study characterized oral and nasal Staphylococcus colonization in healthy young adults and explored the oral cavity as a potential niche for AMR surveillance. Staphylococcus spp. from oral and nasal samples of 101 dentistry students were isolated and identified by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS). Antimicrobial susceptibility was assessed using EUCAST/CLSI guidelines. Longitudinal oral samples from a subgroup were analysed by Fourier Transform Infrared Spectroscopy-Attenuated Total Reflectance (FTIR-ATR) to explore strain persistence and turnover. Staphylococcus colonization was highly prevalent (oral: 91%; nasal: 95%), with 86% concurrent oro-nasal colonization. Staphylococcus epidermidis predominated in both niches. Resistance to ≥ 1 antimicrobial was detected in 80% of coagulase-negative staphylococci (CoNS) and 73% of oral Staphylococcus aureus carriers. Multidrug-resistant phenotypes were found in 10% of CoNS carriers. Although multidrug-resistant and methicillin-resistant S. aureus was not detected, oral S. aureus frequently showed resistance to commonly prescribed dental antibiotics (amoxicillin, erythromycin, and clindamycin). Resistance frequencies were comparable between niches. Oral species-specific colonization dynamics suggested temporal turnover among Staphylococcus warneri and persistence-like clustering for S. aureus in some participants. Oral cavity harbours diverse, frequently antimicrobial-resistant Staphylococcus populations at rates comparable to the nasal cavity. These findings support the oral cavity as a complementary niche for Staphylococcus carriage, highlighting its relevance for future AMR-surveillance strategies in dentistry and human health.

PMID 43049965
阅读全文 →
PubMedTherapeutic advances in gastroenterology2026-11-18

Vonoprazan in school-aged children and adolescents: A narrative review of emerging evidence for gastroesophageal reflux disease and Helicobacter pylori infection.

Jing Yang Y, Yu Yang Y

This narrative review synthesizes available evidence on vonoprazan (VPZ), a potassium-competitive acid blocker (P-CAB) that achieves rapid, potent gastric acid suppression with minimal CYP2C19 dependence, in pediatric patients with gastroesophageal reflux disease (GERD) or Helicobacter pylori (H. pylori) infection. VPZ has been approved for adult indications in Japan (2014) and the United States (2022-2023) but has not received pediatric approval in any country or region as of mid-2026. Current clinical data derive almost exclusively from adolescents (12-17 years) and children aged ≥6 years weighing ≥30 kg; evidence in younger children (<6 years or <30 kg) is essentially absent, and this gap is highlighted throughout. Following the SANRA guidance for narrative reviews, PubMed/MEDLINE and ClinicalTrials.gov were searched through July 2026, supplemented by conference abstracts, reference lists, and regulatory documents, with adult data included where required for pharmacological or bridging rationale. For GERD, clinical evidence remains limited to Phase 1 pharmacokinetic/safety studies in adolescents (VPED-102) and children ≥6 years/≥30 kg (VPED-103), now reported in a peer-reviewed pooled analysis and integrated into a population pharmacokinetic (popPK) model; these confirm adult-concordant VPZ exposures at 10 and 20 mg with acceptable short-term tolerability and no age- or weight-related differences in clearance across 6-54 years, and model-based simulations support the same fixed doses in children as young as approximately 1 year, though no efficacy randomized controlled trial has been completed. For H. pylori eradication, prospective data from Japanese adolescents (n = 645) report a first-line VPZ triple-therapy intention-to-treat eradication rate of 73.6%, below the ≥90% guideline threshold, with clarithromycin resistance identified as a key contributor, while VPZ-based rescue therapy achieved 100% eradication in a small retrospective Western series (n = 11). Pediatric safety data are limited to short-term exposure; long-term effects on growth, bone metabolism, and the gut microbiome remain unstudied. Overall, VPZ is a pharmacologically promising alternative to proton pump inhibitors in pediatric acid-related disease, but current evidence is insufficient to support routine use outside clinical trials, and completion of ongoing randomized controlled trials, pediatric dose optimization, age-appropriate formulations, and long-term safety studies are prerequisites for guideline-level recommendations.

PMID 43048297
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多lansoprazole + amoxicillin + clarithromycin